Latest news with #GeneticTesting
Yahoo
05-08-2025
- Business
- Yahoo
Myriad Genetics (NASDAQ:MYGN) Reports Strong Q2, Stock Jumps 30.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) reported revenue ahead of Wall Street's expectations in Q2 CY2025, but sales were flat year on year at $213.1 million. The company's full-year revenue guidance of $823 million at the midpoint came in 1.5% above analysts' estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts' consensus estimates. Is now the time to buy Myriad Genetics? Find out in our full research report. Myriad Genetics (MYGN) Q2 CY2025 Highlights: Revenue: $213.1 million vs analyst estimates of $202 million (flat year on year, 5.5% beat) Adjusted EPS: $0.05 vs analyst estimates of -$0.01 (significant beat) Adjusted EBITDA: $14.5 million vs analyst estimates of $4.75 million (6.8% margin, significant beat) The company slightly lifted its revenue guidance for the full year to $823 million at the midpoint from $815 million EBITDA guidance for the full year is $30 million at the midpoint, above analyst estimates of $20.53 million Operating Margin: -154%, down from -17.3% in the same quarter last year Free Cash Flow was -$20.5 million compared to -$2.6 million in the same quarter last year Market Capitalization: $366.9 million "We delivered solid second-quarter results, driven by continued strength in hereditary cancer testing in oncology, improving momentum in hereditary cancer testing for unaffected individuals, and favorable pricing trends supported by mix and our ongoing efforts to expand payer coverage. Our disciplined approach to expense management contributed to our improved profitability while we continued to invest in strategic drivers to enable long-term growth," said Sam Raha, President and CEO, of Myriad Genetics. Company Overview Founded in 1991 as one of the pioneers in translating genetic discoveries into clinical applications, Myriad Genetics (NASDAQ:MYGN) develops genetic tests that assess disease risk, guide treatment decisions, and provide insights across oncology, women's health, and mental health. Revenue Growth A company's long-term sales performance can indicate its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Myriad Genetics grew its sales at a mediocre 5.5% compounded annual growth rate. This was below our standard for the healthcare sector and is a poor baseline for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Myriad Genetics's annualized revenue growth of 9.2% over the last two years is above its five-year trend, suggesting some bright spots. This quarter, Myriad Genetics's $213.1 million of revenue was flat year on year but beat Wall Street's estimates by 5.5%. Looking ahead, sell-side analysts expect revenue to remain flat over the next 12 months, a deceleration versus the last two years. This projection doesn't excite us and indicates its products and services will see some demand headwinds. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Adjusted Operating Margin Although Myriad Genetics was profitable this quarter from an operational perspective, it's generally struggled over a longer time period. Its expensive cost structure has contributed to an average adjusted operating margin of negative 1.3% over the last five years. Unprofitable healthcare companies require extra attention because they could get caught swimming naked when the tide goes out. It's hard to trust that the business can endure a full cycle. On the plus side, Myriad Genetics's adjusted operating margin rose by 4.2 percentage points over the last five years, as its sales growth gave it operating leverage. This performance was mostly driven by its recent improvements as the company's margin has increased by 11.2 percentage points on a two-year basis. In Q2, Myriad Genetics generated an adjusted operating margin profit margin of 4%, in line with the same quarter last year. This indicates the company's overall cost structure has been relatively stable. Earnings Per Share Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Myriad Genetics's full-year EPS flipped from negative to positive over the last five years. This is encouraging and shows it's at a critical moment in its life. In Q2, Myriad Genetics reported adjusted EPS at $0.05, in line with the same quarter last year. This print easily cleared analysts' estimates, and shareholders should be content with the results. Over the next 12 months, Wall Street expects Myriad Genetics to perform poorly. Analysts forecast its full-year EPS of $0.11 will hit $0.09. Key Takeaways from Myriad Genetics's Q2 Results This was a beat and raise quarter. We were impressed by how significantly Myriad Genetics blew past analysts' revenue, EBITDA, and EPS expectations this quarter. We were also excited its full-year revenue guidance was raised and full-year adjusted EBITDA guidance was ahead of expectations. Zooming out, we think this quarter featured some very important positives. The stock traded up 30.6% to $5.04 immediately after reporting. Myriad Genetics put up rock-solid earnings, but one quarter doesn't necessarily make the stock a buy. Let's see if this is a good investment. We think that the latest quarter is just one piece of the longer-term business quality puzzle. Quality, when combined with valuation, can help determine if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free.
Indian Express
03-07-2025
- Health
- Indian Express
Do IVF babies have more health problems? Gynaecologist clears the air
Written by Dr Mannan Gupta Many couples who come to me for in-vitro fertilisation (IVF), which entails fertilisation of an egg by a sperm in a laboratory and subsequent implantation of the embryo into the woman's uterus, ask me one question: Will the baby born to them be healthy or be more susceptible to infection? As an assisted reproductive technology (ART), most people assume that IVF children are somehow unnatural and hence vulnerable to illnesses. This presumption, however, is misplaced. Studies show that the vast majority of IVF-conceived children develop normally and achieve milestones as well as naturally conceived children. They go to regular schools, live ordinary lives and enjoy similar long-term health outcomes. Some findings do indicate that IVF babies tend to have a slightly increased risk of low birth weight, premature birth or being small for gestational age. But such a risk is most frequently associated with circumstances such as multiple conception like twins or triplets, older age of the mother or underlying infertility but not IVF. Also premature or low birth weight babies do not develop significant illness later in life. That largely depends on factors such as the health of the parents, the quality of the embryo and the expertise of the fertility clinic providing the treatment. Notably, as IVF technology improves, through single embryo transfer, freezing technology, and improved embryo testing, risks have diminished considerably. Opt for single embryo transfer instead of multiple embryos to reduce the risk of multiple pregnancies, which are associated with higher health risks for both babies and mothers. Preimplantation Genetic Testing (PGT) can be performed on embryos before they are implanted. This can help identify and select embryos without chromosomal abnormalities, reducing the risk of birth defects. Ensure the health of the mother before and during pregnancy is optimum. This includes a lifestyle discipline, managing pre-existing health conditions and addressing any potential risks that may affect pregnancy. Couples need to be counselled so that they can make informed decisions based on their specific circumstances. Regular monitoring and follow-ups during pregnancy can help both the mother and the developing foetus last out the full term. Science has revolutionized IVF to the extent that it is not only effective but also safe for mothers and babies alike. Couples considering IVF ought to see fertility specialists, adhere to set guidelines and not be discouraged by myths. (The author is Chairman & HOD, Obstetrics & Gynaecology, Elantis Healthcare, New Delhi)
Hans India
02-06-2025
- Health
- Hans India
Dr. S. Vyjayanthi: Transforming Fertility Care with Cutting-Edge Reproductive Technologies in India
Hyderabad, India – Dr. S. Vyjayanthi, a distinguished fertility specialist and reproductive medicine expert, is making waves in the field of assisted reproductive technology (ART), offering hope and cutting-edge solutions to couples struggling with infertility. As the Founder and Director of MotherToBe Fertility Centre and the Head of Department & Consultant Fertility Specialist at KIMS Fertility Centre, Dr. Vyjayanthi has been at the forefront of IVF advancements, fertility preservation, and personalized fertility treatments for over two decades. With a track record of over 10,000 successful IVF cycles and a reputation for handling some of the most complex infertility cases, Dr. Vyjayanthi is recognized as one of the leading fertility experts in India. She has dedicated her career to helping couples achieve parenthood, integrating scientific expertise, compassionate care, and state-of-the-art technology to ensure high success rates in fertility treatments . Pioneering Fertility Solutions with Expertise and Innovation Dr. Vyjayanthi's extensive international training in reproductive medicine has equipped her with a deep understanding of the complexities of infertility. She holds a Subspecialty Accreditation in Reproductive Medicine & Surgery from the Royal College of Obstetricians and Gynaecologists (RCOG), UK, making her one of the few clinicians in India to have received this prestigious recognition. Her expertise includes: In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Advanced Fertility Preservation Techniques (Egg & Embryo Freezing) Treatment for Low AMH & Poor Ovarian Reserve Management of Polycystic Ovary Syndrome (PCOS) & Endometriosis Recurrent Implantation Failure & Miscarriage Solutions Preimplantation Genetic Testing (PGT) for Healthy Embryos Comprehensive Male Infertility Treatments Fertility preservation-egg freezing, embryo freezing and semen freezing-cancer patients and other benign conditions and age related fertility decline. Under her leadership, MotherToBe Fertility Centre has established itself as a center of excellence in fertility treatments, offering personalized patient care, ethical medical practices, and world-class success rates. Revolutionizing Fertility Care with the Latest IVF Innovations With the ever-evolving advancements in reproductive medicine, Dr. Vyjayanthi ensures that her clinics stay ahead of the curve by adopting the latest ART technologies to maximize pregnancy success rates. Some of the cutting-edge innovations she has introduced include: Time-Lapse Embryo Monitoring – A non-invasive technique that helps select the healthiest embryos for implantation. Preimplantation Genetic Testing (PGT) – Ensuring the transfer of chromosomally normal embryos to increase success rates. Artificial Intelligence in IVF – Using AI-powered embryo selection to enhance implantation potential. Ovarian Rejuvenation Therapy – Offering hope to women with poor ovarian reserve or early menopause. Natural Cycle & Minimal Stimulation IVF – An alternative for women who prefer gentler, low-medication treatments. Stem Cell Therapy for Endometrial Receptivity – Aiding women with thin endometrium or recurrent implantation failure. These technological advancements, combined with Dr. Vyjayanthi's personalized treatment protocols, have made MotherToBe Fertility Centre one of the top fertility clinics in India. A Voice for Fertility Awareness and Women's Health Beyond clinical practice, Dr. Vyjayanthi is a strong advocate for fertility awareness and reproductive health. She actively participates in global conferences, research initiatives, and training programs, ensuring that medical professionals and patients alike benefit from the latest scientific breakthroughs. Recently, she was invited to Zimbabwe to conduct a high-level seminar on IVF and fertility treatments, where she addressed 120+ representatives from women's organizations and high-level officials, including First Lady Dr. Auxillia Mnangagwa and Indian Ambassador Mr. Khanduja. The seminar, organized in collaboration with the Tasimba Siyanqoba Foundation and KIMS Hospitals, was a major milestone in global fertility education. Her expertise has also been sought after for: International fertility conferences Guest lectures on advanced reproductive treatments Awareness campaigns on infertility and egg freezing Workshops on optimizing IVF success rates By leading such initiatives, Dr. Vyjayanthi is shaping the future of reproductive medicine, breaking the stigma around infertility, and empowering couples with knowledge and treatment options. MotherToBe: A Center of Excellence in Fertility Treatments MotherToBe Fertility Centre has emerged as a beacon of hope for couples facing infertility. The clinic is equipped with state-of-the-art embryology labs, cutting-edge fertility technology, and a dedicated team of fertility specialists, making it one of India's most trusted IVF centers. Some key highlights of MotherToBe's success: 65% Blastocyst Pregnancy Rate in women under 35 80% Donor Egg Conception Rate 70% Frozen Embryo Transfer Success Rate Comprehensive Fertility Preservation Services Highly Ethical & Transparent Medical Practices With a patient-centric approach, high success rates, and a commitment to innovation, MotherToBe Fertility Centre continues to set new benchmarks in fertility care. A Trusted Expert in Reproductive Medicine
